laboratori corp america hldg
despit lower outlook valu
strategi trough valu ep
miss miss dont believ labcorp underli result bad
market volatil would suggest vs
diagnost drove quarterli weak revenu growth came
expect surpris volum weak nation
lab report quarter light current posit econom condit
doesnt appear fundament chang landscap silver line
covanc result strong post organ growth quarterli book-
to-bil ultim weaker result lead lower ep outlook
believ repres floor ep growth ceo dave king
commit modest growth see three swing factor ebitda
includ pama headwind aet/unh headwind
share normal quest covanc launchpad save y/i
opportun dx given lower trajectori conserv
view capit deploy reset ep forecast
previous still view capit deploy major lever
remain bullish potenti share gain across busi give us
convict new baselin serv ep floor also lower pt
take step back labcorp thesi unchang believ compani
remain well posit across franchis custom consolid share
partner offer premium servic high valu see number lever
share gain time first labcorp improv competit
posit dx nation payor network open access encourag
share shift toward prefer network second pama price transpar
highlight valu proposit labcorp dx busi model third walgreen
partnership improv access patient consumer-friendli set
view recent under-perform driven neg sentiment around
present attract entri point believ compani approach floor
valuat ep reiter labcorp top pick ow
lh quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
barclay laboratori corp america hldg
laboratori corp america hldg lh
overweight labcorp remark track
record execut led lead organ
growth augment value-enhanc
acquisit covanc acquisit continu
theme expect expertis
organ posit labcorp premier
partner choic companion diagnost play
greater role clinic decis make
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceler revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
barclay laboratori corp america hldg
miss miss dont believ labcorp underli result bad
market volatil would suggest vs diagnost drove
quarterli weak revenu growth came expect
due partial juli ransomwar attack hurrican florenc weaker volum
environ excess fix cost lab cost structur led pressur lab oper
margin y/i surpris volum weak
nation lab report quarter light current posit econom condit
doesnt appear fundament chang landscap silver line
covanc result strong post organ growth quarterli book-to-bil
combin strong growth cost save initi drove covanc margin
expans y/i ultim labcorp earn weaker
expect compani lower outlook
believ repres floor ep growth ceo dave king commit
modest growth next year see three swing factor ebitda
math repres net headwind growth includ pama
headwind aet/unh headwind share normal quest
contract open covanc launchpad save y/i
potenti opportun dx given pressur well lower
trajectori conserv view capit deploy reset
ep forecast previous still view capit
deploy major lever model assum labcorp exit net leverag
ebitda addit remain bullish potenti share gain across
busi give us convict new baselin serv ep floor
also lower pt
take step back labcorp thesi unchang believ compani remain
well posit across diagnost drug develop busi custom
consolid share partner offer premium qualiti servic high valu
see number lever drive share gain labcorp time first
labcorp improv competit posit diagnost
nation payor network open access nation lab encourag share shift
toward prefer network second pama price transpar highlight valu
proposit labcorp dx busi model third believ labcorp partnership
walgreen improv access patient consumer-friendli set dx
drug develop view recent under-perform driven neg
sentiment around present attract entri point believ compani
approach floor valuat ep reiter labcorp top pick
barclay laboratori corp america hldg
lab current trade discount averag ntm price-to-earnings
lab trade discount though continu potenti share gain nation payor network open
lower price target given lower earn forecast driven
uncertain near-term outlook lab busi price target
repres adj ebitda estim billion adj ep
estim prior price target repres prior asj
ebitda estim billion adj ep forecast
labcorp lower revenu ep guidanc account busi
disrupt quarter well chang fx labcorp expect revenu
barclay laboratori corp america hldg
growth midpoint previou guidanc
emb headwind busi disrupt quarter increment
expect fx headwind covanc constant currenc growth expect rang
midpoint believ target emb
acquir growth mid- high-singl digit organ growth fx
tailwind total growth expect y/i labcorp diagnost expect show
total growth vs previous constant currenc growth vs
previous rel previou guidanc emb increment
headwind fx busi disrupt quarter
ep guidanc lower midpoint labcorp
estim busi disrupt headwind ep also note
oper fell short expect quarter new ep rang repres
growth y/i remind ep forecast includ benefit tax
reform assum tax rate ad growth y/i
addit labcorp size expect impact pama headwind
free cash flow guidanc reduc million midpoint due million
tax payment food solut sale anticip paid
pleas see report
risk/reward new payor
paradigm upgrad ow
continu see renew end exclus contract nation
payer real strateg posit nation lab labcorp quest
remind labcorp quest recent announc new contract
aetna view game-chang industri previous labcorp quest
exclus relationship aetna respect
open januari overal believ new contract help break
guidanc dx dx dx organ organ growth barclay laboratori corp america hldg
barrier nation lab consolid share test improv patient
experi payor
think could big deal share save prefer lab
volum shift high-cost set first lab industri volum
shift high-cost provid toward prefer network plan
develop pool save share provid instead
commodit lab lab result qualiti metric differenti
particip price tool incentiv effici deliveri care encourag
util prefer network also consid put place
econom incent patient physician adher network would
also first histori lab industri would includ waiv out-of-pocket
cost patient co-pay deduct encourag adopt given
rapid growth high-deduct health plan past decad believ could
drive strong incent patient better direct shift volum
continu think share dynam labcorp quest vs rest industri
far materi relev share dynam two nation lab
said obvious share shift quest labcorp
aetna contract open believ
net yield modest benefit quest modest headwind labcorp
simpl math larger aetna would suggest quest net
beneficiari vice versa labcorp said fact labcorp earn price
increas critic element deal calculu also
cement truli paradigm shift industri base case analysi
assum around ebitda tailwind quest around
ebitda headwind labcorp
barclay laboratori corp america hldg
base case estim potenti price/mix chang labcorp contract mm
clearli much bigger opportun labcorp quest test consolid
lab across payor repres industri look back
past decad obviou nobodi origin nation exclus
contract nation lab nation payor patient clear
nation payor recogn need work nation lab better drive
valu system old contract allow region lab better penetr physician
offic could arbitrag benefit fact nation lab out-
of-network one nation payor drove higher price nation payor
overal higher out-of-pocket cost patient quest believ old payor
paradigm drove complex physician would field question
patient around unexpect lab cost back in-network remov unnecessari
barrier compet nation lab believ share could move quickli
commerci execut get messag number
get larg quickli current valuat believ investor free call option
potenti consolid upsid outsid hospit lab opportun size
around billion nation lab repres share
payor enu shift mmlabcorpquesttot labstot totalunitedhealth chang chang aet aet shift mmlabcorpquesttot labstot totaltot aet chang payor payor compani impact mmlabcorpquesttot ebitda compani ebitda barclay laboratori corp america hldg
total revenu growth lab busi
organ revenu growth lab busi
adjust sale food solut busi volum quarter
increas includ organ growth impact
hurrican florenc ransomwar attack headwind volum growth
quarter one less workday easier comp hurrican off-set one
anoth put move part togeth estim underli
util increas y/i repres deceler q/q
trend given season trend consum test y/i tailwind growth
modest sequenti basi labcorp post y/i
declin rev-per-req ex-food sale attribut pama
ransomwar attack also believ includ roughli headwind
fx believ test mix genom esoter test like help off-set
price headwind compar believ headwind price
test like modest
note organ reimburs growth adjust fx beacon lb
labcorp adjust mix
barclay laboratori corp america hldg
covanc deliv organ growth total growth well
forecast growth rate basi unclear impact
time pass-through revenu quarter labcorp note three
segment covanc grew quarter strongest growth come
earli develop busi believ covanc organ growth rate larg
consist sequenti though difficult know sure given compani didnt
disclos precis organ growth rate compani optimist around
covanc competit market guid toward organ growth
mid- to-high-singl digit
covanc post net book-to-bil base mark
signific improv estim net book-to-bil
someth believ well receiv ttm basi labcorp book-to-bil
manag continu enthusiast around integr offer
elabor success compani area clinic trial recruit
joint analyt companion diagnost develop commerci
compani note covanc integr offer key attract new
millionsestestfisc year end dec labcorp metricstot growth organ growth lab lab growth acquir total access organ net new weather calendar underli ppa beacon organ lab rev medicar pama overal y/i organ growth barclay laboratori corp america hldg
segment organ growth labcorp
labcorp activ new acquisit partnership divestitur
impact pace growth throughout recent partnership mount
sinai appalachian region healthcar baptist health continu momentum
organ growth modest compani done effect job
win new busi hospit partnership acquisit continu
believ effort provid better healthcar integr patient cost share
greater regul fda ldt reimburs pressur pama driver
share consolid toward effici provid labcorp quest
us market continu fragment share repres
two independ market leader believ reimburs pressur drive lab
consolid smaller competitor lack scale drive effici busi
margin come increas pressur rel quiet
deal front activ year labcorp kick deal activ
acquisit mt sinai outreach oper follow sizabl paml acquisit
ad million refer lab test busi affili provid health
organ growth labcorp dxcovanc drug affili lab barclay laboratori corp america hldg
system cathol health initi quest activ year acquisit
announc total eight deal headlin million acquisition/partnership
peacehealth
million acquisit
medfusion/clearpoint texa final sonic gotten action two jv
nyu nyc western connecticut network deal activ easili
eclips million lab industri revenu aggreg us
industri revenu look chart clear pace
partnership acquisit pick
 clinic laboratori acquisit partnership
believ uptick laboratori deal activ partial attribut pama
uncertainti major driver thesi industri updat
reimburs laboratori test went effect januari clearli
mind industri particip hospit laboratori view non-cor part
health system ideal area hospit gener save strike deal
labcorp quest allow hospit focu core busi continu
provid patient access qualiti laboratori servic mani hospit system
alreadi financi pressur pama repres increment risk drive
manag team chang decision-mak
octob labcorp announc multi-year laboratori partnership
baptist health two organ build upon exist refer laboratori
arrang go five year expand
arrang includ technic servic labcorp provid enhanc
laboratori technolog data analyt help health system improv patient
care baptist health oper eight hospital-bas laboratori fall
scope agreement
march labcorp announc multi-year partnership appalachian
region healthcar labcorp provid technic servic appalachian region
healthcar hospital-bas lab refer test servic entir network
facil clinician labcorp also grant appalachian region healthcar access
enhanc inform technolog data analyt help improv deliveri
yeardealslabtarget/partnerdatetyp medic outreach lab immunotec us lab lab lab region serviceslabcorpcalifornia laboratori associ outreach acquisitionquestcleveland clinic servicesquesthartford outreach acquisitionquestshiel medic laboratori jvquestcap cod healthcar outreach acquisitionquestm fusion associ medic laboratori laboratori outreach acquisit servicessonicwestern connecticut health network venturequestmontefior health serviceslabcorpmount acquisitionlabcorpclearpath lab lab acquisitionquesthca serviceslabcorphenri mayo newel acquisitionquestclin laboratori partner hartford health outreach acquisit barclay laboratori corp america hldg
patient care appalachian region healthcar oper hospit kentucki
februari labcorp announc agreement acquir patholog
associ medic laboratori paml mark largest laboratori acquisit
notabl deal labcorp paml larg hospital-own laboratori
provid refer outreach test servic hospit partner asset
own jv provid servic provid cathol
initi chi two largest hospit system countri addit paml
labcorp also plan acquir lab interest number joint ventur
believ would ultim lead complet ownership busi announc
transact clearli valid labcorp commit expand partnership
anchor hospit system come close heel acquisit
mt sinai outreach busi term disclos news report
suggest paml million revenu estim could add
revenu growth annual basi lab growth
acquisit expand labcorp presenc pacif northwest mid-west south
give compani access serv two largest health system
januari labcorp announc acquir clinic outreach
lab asset mount sinai health system nyc believ highlight
compani focu busi develop health system also repres
nice tuck-in acquisit compani system give labcorp access serv
anchor health system nyc market offer clinic patholog test
includ cytolog relat mdx test addit labcorp oper
mount sinai patient servic center psc region ad exist local
network psc opportun could includ collabor clinic trial
strengthen resourc covanc well work companion diagnost
medic educ term size estim transact could add
top line growth run-rat basi addit april
announc labcorp mount sinai enter contract
labcorp would work standard process test menu equip logist
health network seven acut care hospit
implement medicar clinic lab fee schedul kick
largest chang diagnost reimburs year result confirm
belief pama lead meaning medicar cut time lead
period heighten lab industri consolid labcorp size pama expect
headwind revenu growth headwind ep remind
price reduct drop earn outsiz
impact ep growth y/i financi impact still meaning yet manag
given medicar clf repres labcorp diagnost revenu
total medicar reimburs chang actual sizabl survey work
interact lab director suggest industri experi period meaning
consolid ultim believ smaller lab outsiz medicar exposur
consolid time either organ inorgan benefit labcorp quest
industri leader
quot headlin medicar cut clf time roughli
code see rate decreas vs rate increas code
rate reduct greater labcorp quest estim around
top code see rate reduct annual first year reduct
increasingli sever routin test estim top
hcpc code clf spend cut altogeth top code
pleas see report
barclay laboratori corp america hldg
contribut clf spend almost million claim
design top code gener billion clf payment
top code cut genom health oncotyp dx top code
increas top code cut impli
medicar reimburs payment still weight median
averag addit anoth three test cut display magnitud
futur cut top code includ lipid panel reduct
code contribut nearli clf spend code drug
test def class new volum weight median pama reduct
overal continu believ signific rate reduct routin code
lead increas outsourc effici provid labcorp quest
top hcpc code clf spend
potenti off-set horizon propos physician
fee schedul announc seek public comment definit chang
applic lab could broaden scope lab survey next pama data
reimburs depend number addit hospit outreach lab
survey report period clear chang view
expect medicar rate cut pama rate lock
data report period remind data report take place everi
year said think market may view posit given potenti
rate increas relief futur cut current model addit cut
hcpc codehcpc code descriptiontot claim linestot payment total nlaweight median payment w/ payment w/ payment w/ thyroid stim metabol cbc w/auto diff hemoglobin test def panel total test def parathormon psa free culture/coloni test def test def natriuret colorect breast cbc folic acid suscept barclay laboratori corp america hldg
pleas see report
takeaway clfs/pama
propos
histor defin applic lab base lab nation provid identifi
npi whether medicar revenu gener npi
clf hospit lab npi sit parent hospit level given
hospit gener major revenu ipp opp fee schedul vs
clf npi applic lab definit exclud mani hospit lab data
collect period vast major data submit pama data
collect period labcorp quest seek comment
whether use file bill type clia certif number
would recommend read brief section page propos
describ merit drawback use clia certif number
agenc chose use past lab industri histor lobbi
use clia number would put focu back lab report entiti
possibl major hospit lab medicar revenu clf
caveat clia number may repres entir hospit lab rather
outreach lab ipps/opp payment may larger clf revenu
broader inclus hospit outreach lab could lead increas medicar
reimburs base volume-weighted-median rate submiss
labcorp quest undoubtedli still domin data collect period
inclus higher cost lab could lift higher wherev volum weight median lie
labcorp report revenu billion forecast driven
acquir growth acquir less divest eurofin collect
higher model off-set lower organ growth lower
ransomwar hurrican florenc collect headwind fx headwind
labcorp dx revenu billion includ organ growth coupl
acquir growth off-set fx headwind impact divest
covanc food solut busi drive overal declin y/i came
forecast growth due partial aforement
busi disrupt impact volum growth came
estim organ volum forecast y/i
due partial busi disrupt mark weaker result
labcorp organ revenu growth histor stronger
peer continu acquisit ad volum growth
adjust covanc food sale fx revenu per requisit decreas
y/i forecast keep mind pama
headwind within rev-per-req mix drive chang
covanc revenu billion estim
unclear reimburs revenu impact quarter revenu increas
y/i constant currenc growth adjust fx growth
driven organ contribut acquir growth ttm
book-to-bil labcorp note quarterli
book-to-bil view relief
compani post quarterli book-to-bil
barclay laboratori corp america hldg
quarterli revenu million organ growth
adjust ebit ex-amort declin y/i million adj ebit
margin percentag net revenu declin y/i
estim adjust oper margin increas covanc
declin labcorp diagnost segment labcorp diagnost margin declin
y/i covanc drug develop margin improv
improv labcorp diagnost segment margin acquisit
volum growth off-set neg impact pama ransomwar
attack disposit food busi personnel cost covanc saw benefit
covanc launchpad program top-lin growth chiltern acquisit
labcorp remain track gener million save
expans launchpad includ covanc well million cost synergi
integr chiltern end addit earn labcorp note
plan begin addit launchpad initi lab busi
anticip similar magnitud prior initi million
growth y/i barclay laboratori corp america hldg
adj ebit margin segment ex-corpor overhead
sg repres net revenu quarter modestli
estim import note due account chang
 expens optic decreas percentag revenu
sg trend revenu
revenu higher expect ebitda margin
came expect due stronger revenu
off-set higher expect cost revenu
sg abad debt lab barclay laboratori corp america hldg
margin trend revenu
flow oper came million estim
million cffo repres adjust net incom quarter capital-expenditure
million repres net revenu y/i capit deploy
consist million share repurchas labcorp deploy billion
toward chiltern paml mt sinai outreach toward share
labcorp continu gener signific free cash flow believ flexibl
even chiltern activ capit deploy market
compani expect gener free cash flow rang million
billion billion previou guidanc lower free cash flow
estim result upcom million tax payment relat food solut
sale eurofin labcorp exit net debt ebitda
use oper million
marginsebit flowcapex barclay laboratori corp america hldg
labcorp mm except ep reportedincom growth ebitda ebit pre-tax tax net adj net researchprior yearprior quarter barclay laboratori corp america hldg
million except per share dataestestestestestestestestestfisc year end dec growth debt gross lab growth growth ex-fx organ growth increas gross cro net growth net margin net comp net net net intang loss equiti ebitda margin net net ebit margin net expens net debt pre-tax pre-tax incom tax net net average share average share ep ep increas item net incom adj net margin net increas dilut increas ebit adj ebit margin barclay laboratori corp america hldg
labcorp statement flow
estestestestestestestestest loss sale interest zero coupon earn excess incom expens expens chang work y/i adj net sale payment paid invest revolv credit term vendor-financ debt issuanc payment interest interest tax benefit stock proce issuanc common per growth y/ynet financ exchang increase/decreas begin end adj net debt ttm barclay laboratori corp america hldg
receiv expens incom equip equiti equityaccount payabl expens coupon-subordin credit incom portion credit coupon-subordin senior senior less current leas incom sharehold liabilit barclay laboratori corp america hldg
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
